Showing 2951-2960 of 4063 results for "".
- Verana Health Presents Geographic Atrophy and Diabetic Macular Edema Research at ASRS 2022https://modernod.com/news/verana-health-presents-geographic-atrophy-and-diabetic-macular-edema-research-at-asrs-2022/2480976/Verana Health delivered two podium presentations at the American Society of Retina Specialists annual meeting in New York City on July 15. The research findings were generated through analysis of Ophthalmology Qdata, real-world data resulting from the curation
- NPR Report: He and His Wife Both Got Cataract Surgery. His Bill Was 20 times Higher Than Hershttps://modernod.com/news/npr-report-he-and-his-wife-both-got-cataract-surgery-his-bill-was-20-times-higher-than-hers/2480934/A NPR report shares an example of the factors involved in how insurance companies determine reimbursement for cataract surgery. The articl
- Vision Expo West 2022 Opens Hotel Reservationshttps://modernod.com/news/vision-expo-west-2022-opens-hotel-reservations/2480917/The Vision Council and RX, co-organizers of Vision Expo, announced that reservations are now being accepted at Vision Expo West’s partner hotels for
- Nicox Now Expects Topline Results from NCX 470 Mont Blanc Phase 3 Glaucoma Trial in November 2022https://modernod.com/news/nicox-now-expects-topline-results-from-ncx-470-mont-blanc-phase-3-glaucoma-trial-in-november-2022/2480892/Nicox SA announced that it has closed screening for additional patients in its phase 3 Mont Blanc clinical trial of NCX 470 0.1% in patients with open-angle glaucoma or ocular hypertension. Therefore, the company now expects
- Submissions Now Being Accepted for Innovation Stage Speakers and Content for Vision Expo West 2022https://modernod.com/news/submissions-now-being-accepted-for-innovation-stage-speakers-and-content-for-vision-expo-west-2022/2480883/The Vision Council and RX, co-organizers of Vision Expo, announced that submissions are being accepted for Innovation Stage speakers, presentations and panels for
- Lumenis OptiLight Wins 2022 MedTech Breakthrough Award: "Best New Technology Solution for Ophthalmology"https://modernod.com/news/lumenis-optilight-wins-2022-medtech-breakthrough-award-best-new-technology-solution-for-ophthalmology/2480882/
- Tarsus Presents New Findings From Two Studies That Demonstrate the Impact of Demodex Blepharitis at the ARVO 2022 Annual Meetinghttps://modernod.com/news/tarsus-presents-new-findings-from-two-studies-that-demonstrate-the-impact-of-demodex-blepharitis-at-the-arvo-2022-annual-meeting/2480847/Tarsus Pharmaceuticals, Inc. presented data from its Atlas Continuation study on the negative impact Demodex blepharitis has on daily life and visual function among certain patient groups, as well as preliminary findings from the Pandora study on the coexisting bacterial burden for patients with
- Clearside Biomedical Poster Presentation at ARVO 2022 Annual Meeting Demonstrates Versatility of Suprachoroidal Delivery Technologyhttps://modernod.com/news/clearside-biomedical-poster-presentation-at-arvo-2022-annual-meeting-demonstrates-versatility-of-suprachoroidal-delivery-technology/2480845/Clearside Biomedical, Inc. announced that several poster presentations were delivered on Clearside’s proprietary suprachoroidal delivery platform, XIPERE®, and gene therapy delivery utilizing Clearside’s SCS Microinjector® at the Association for Research in Vision and Ophthalm
- Ora Unveils Ophthalmic Research Technologies at ARVO 2022https://modernod.com/news/ora-unveils-ophthalmic-research-technologies-at-arvo-2022/2480833/From advancements in retinal and dry e
- Ocuphire Completes Last Clinical Trial Supporting the Planned 2022 NDA Submission of Nyxol for Reversal of Mydriasishttps://modernod.com/news/ocuphire-completes-last-clinical-trial-supporting-the-planned-2022-nda-submission-of-nyxol-for-reversal-of-mydriasis/2480812/Ocuphire Pharma announced positive results in the MIRA-4 pediatric safety trial investigating its product candidate Nyxol for the reversal of pharmacologically-induced mydriasis (dilation of pupil). The results demonstrated that Nyxol’s efficacy and safety in pediatric subjects 3-11 ye